Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · June 19, 2024

Safety and Efficacy of Dupilumab in Children With Atopic Dermatitis Aged 6 Months to 5 Years

American Journal of Clinical Dermatology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Clinical Dermatology
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Am J Clin Dermatol 2024 May 14;[EPub Ahead of Print], AS Paller, EC Siegfried, EL Simpson, MJ Cork, R Sidbury, IH Chen, FA Khokhar, J Xiao, A Dubost-Brama, A Bansal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading